DYAX said in its Q4 CC that the focus of their discussions with FDA is a "safe use program" for DX-88 and gave the impression that this is the last step before approval. Call Transcript: <a href="http://seekingalpha.com/article/122649-dyax-corp-q4-2008-earnings-call-transcript?source=yahoo" target="_blank">http://seekingalpha.com/article/122649-dyax-corp-q4-2008-earnings-call-transcript?source=yahoo</a>